Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03164772
Title Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Ludwig Institute for Cancer Research

lung non-small cell carcinoma


BI 1361849 + Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST